Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Hao Jiang & Shan-Shan Chen & Bin Jiang & Qian Jiang & Ya-Zhen Qin & Yue-Yun Lai & Xiao-Jun Huang
- چاپ و سال / کشور: 2010
Description
The purpose of our study is to compare the 7-year response to imatinib monotherapy as an initial treatment and re-treatment in Chinese patients with chronic myelogenous leukemia-chronic phase (CML-CP) patients in a single center in Beijing. A retrospective study of 171 CML-CP patients receiving imatinib monotherapy was done with 73 in the initial treatment group (disease course .6 months) and 98 in the re-treatment group (disease course >6 months). Cumulative rates of complete cytogenetic response (CCyR) at 6, 12, and 36 months after imatinib treatment in the initial and re-treatment groups were 75%, 89%, and 96%, and 48%, 77%and 84%(p= 0.0002), respectively. The median time to CCyR in the initial and re-treatment groups was 6 months (95% CI, 3.3.8.3) and 9 months (95% CI, 6.4.11.6), respectively (p=0.0002). Cumulative rates of major molecular responses at 9, 12, and 18 months after imatinib treatment in the initial and retreatment groups were 31%, 48%, and 60%, and 15%, 25% and 37% (p=0.017), respectively. The median time to the major molecular response in the initial and re-treatment groups was 15 months (95% CI, 12.3.17.7) and 36 months (95% CI, 25.9.46.0), respectively (p=0.017). Progression-free survival at 84 months in the initial and re-treatment groups was 97% and 85%, respectively (p=0.09). Event-free survival at 84 months in the initial and re-treatment groups was 92% and 70%, respectively (p=0.049). Only two of the 171 patients discontinued imatinib therapy for grade 3/4 adverse events. Our study revealed that CML-CP patients would benefit from early treatment with imatinib.
Ann Hematol (2011) 90:41–46 DOI 10.1007/s00277-010-1031-0 Received: 4 May 2010 / Accepted: 12 July 2010 / Published online: 29 July 2010
